Tauopathies
24
8
8
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.2%
1 terminated out of 24 trials
92.3%
+5.8% vs benchmark
4%
1 trials in Phase 3/4
33%
4 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (24)
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
CW2IP2: Imaging and Diagnostic Assessments
Validation of Blood Biomarkers for Alzheimer's Disease
[18F]NIDF PET Imaging in Tau-related Diseases
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
Tau PET/CT in Various Tau-Related Disease Patients
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations